<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120028</url>
  </required_header>
  <id_info>
    <org_study_id>CTSU3C1</org_study_id>
    <secondary_id>2008-008553-27</secondary_id>
    <secondary_id>ISRCTN88894088</secondary_id>
    <nct_id>NCT01120028</nct_id>
  </id_info>
  <brief_title>Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy</brief_title>
  <acronym>3C</acronym>
  <official_title>Open-label, Randomised Multicentre Study of CAMPATH-1H Versus Basiliximab Induction Treatment and Sirolimus Versus Tacrolimus Maintenance Treatment for the Preservation of Renal Function in Patients Receiving Kidney Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health Service, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 3C study is investigating whether reducing exposure to calcineurin inhibitors (by using
      more potent antibody induction treatment and/or an elective switch to sirolimus) can improve
      the function and survival of kidney transplants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term survival of kidney transplants has not improved over the past decade despite
      reductions in the rate of acute rejection. The commonest cause of late graft loss is chronic
      allograft nephropathy which is frequently caused by calcineurin inhibitor toxicity.
      Therefore, it may be possible to improve long-term graft outcomes by reducing the amount of
      calcineurin inhibitor exposure.

      Two possible strategies to do this were tested. Firstly, Campath-1H (a monoclonal
      lymphocyte-depleting antibody) was compared to standard basiliximab-based induction. All
      patients then received tacrolimus-based maintenance therapy for 6-months (using lower doses
      in the Campath-1H arm).

      At six months, patients were re-randomized between remaining on tacrolimus and converting to
      sirolimus (and therefore no longer taking calcineurin inhibitors). Patients were then
      followed-up in clinic and through routine NHS registries to collect information on relevant
      outcomes (including graft function, survival, hospitalisations and death).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2010</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy</measure>
    <time_frame>6 months post-transplantation</time_frame>
    <description>Occurence of biopsy-proven acute rejection events at 6-months after transplantation during Period 1 (randomization to induction therapy (Campath-1H and Tacrolimus, or Basiliximab and Tacrolimus))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft Function (at 18-months After Randomization to Maintenance Therapy)</measure>
    <time_frame>2 years post-transplantation</time_frame>
    <description>Estimated glomerular filtration rate (estimated using MDRD formula) at 18-months after maintenance therapy randomization to either Sirolimus or Tacrolimus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Failure (at 6-months After Randomization to Induction Therapy)</measure>
    <time_frame>6 months post-transplantation</time_frame>
    <description>Return to dialysis or re-transplantation by 6-months after randomization to induction therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Failure (at 18-Months After Randomization to Maintenance Therapy)</measure>
    <time_frame>2 years post-transplantation</time_frame>
    <description>Return to dialysis or re-transplantation by 18-months after randomization to maintenance therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Infection (at 6-months After Randomization to Induction Therapy)</measure>
    <time_frame>6-months post-transplantation</time_frame>
    <description>Occurrence of any serious infection (opportunistic or requiring admission to hospital) reported within Period 1 (randomization to induction therapy of either Alemtuzumab (Campath-1H) and Tacrolimus, or Basiliximab and Tacrolimus).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Infection (at 18-months After Randomization to Maintenance Therapy)</measure>
    <time_frame>2 years post-transplantation</time_frame>
    <description>Occurrence of any serious infection (opportunistic or requiring admission to hospital) reported during Period 2 (maintenance therapy randomization to either Sirolimus or Tacrolimus).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cancer (at 18-months After Randomization to Maintenance Therapy)</measure>
    <time_frame>2 years post-transplantation</time_frame>
    <description>Occurrence of any cancer reported during Period 2 (maintenance therapy randomization to either Sirolimus or Tacrolimus).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Vascular Event (at 18-months After Randomization to Maintenance Therapy)</measure>
    <time_frame>2 years post-transplantation</time_frame>
    <description>Composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death or arterial revascularization</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">852</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab/Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy allocation: Alemtuzumab (Campath-1H).
Maintenance therapy allocation (at 6-months post-transplant): Sirolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alemtuzumab/Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy allocation: Alemtuzumab (Campath-1H).
Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basiliximab/Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy allocation: Basiliximab.
Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basiliximab/Sirolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy allocation: Basiliximab.
Maintenance therapy allocation (at 6-months post-transplant): Sirolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart</description>
    <arm_group_label>Alemtuzumab/Sirolimus</arm_group_label>
    <arm_group_label>Alemtuzumab/Tacrolimus</arm_group_label>
    <other_name>Campath-1H</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>20 mg intravenously, two doses 96 hours apart</description>
    <arm_group_label>Basiliximab/Sirolimus</arm_group_label>
    <arm_group_label>Basiliximab/Tacrolimus</arm_group_label>
    <other_name>Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL</description>
    <arm_group_label>Alemtuzumab/Sirolimus</arm_group_label>
    <arm_group_label>Basiliximab/Sirolimus</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.</description>
    <arm_group_label>Alemtuzumab/Tacrolimus</arm_group_label>
    <arm_group_label>Basiliximab/Tacrolimus</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men or women aged over 18 years

          -  recipient of kidney transplant (planned in next 24 hours)

        Exclusion Criteria:

          -  recipients of multi-organ transplant

          -  previous treatment with Campath-1H

          -  active infection (including HIV, hepatitis B or C)

          -  history of anaphylaxis to humanized monoclonal antibody

          -  history of malignancy (except adequately treated non-melanoma skin cancer)

          -  loss of kidney transplant within 6 months not due to technical reasons

          -  medical history that might limit the individual's ability to take trial treatments for
             the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Friend</last_name>
    <role>Study Director</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Colin Baigent</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin J Landray</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Harden</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Haynes</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxon</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry &amp; Warwickshire</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool and Broadgreen University Hospitals NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bart's and the London NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas's NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hampstead NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester NHS Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle-upon-Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plymouth Teaching Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Trust</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.3cstudy.org/</url>
    <description>3C study website</description>
  </link>
  <results_reference>
    <citation>3C Study Collaborative Group, Haynes R, Harden P, Judge P, Blackwell L, Emberson J, Landray MJ, Baigent C, Friend PJ. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet. 2014 Nov 8;384(9955):1684-90. doi: 10.1016/S0140-6736(14)61095-3. Epub 2014 Jul 28.</citation>
    <PMID>25078310</PMID>
  </results_reference>
  <results_reference>
    <citation>3C Study Collaborative Group. Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial. Am J Transplant. 2018 Jun;18(6):1424-1434. doi: 10.1111/ajt.14619. Epub 2018 Jan 9.</citation>
    <PMID>29226570</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2010</study_first_posted>
  <results_first_submitted>June 10, 2019</results_first_submitted>
  <results_first_submitted_qc>September 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2019</results_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplantation</keyword>
  <keyword>Alemtuzumab</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Basiliximab</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Campath-1H</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Proposals for substudies must be approved by the Steering Committee. Procedure for accessing the data for this study are available on https://www.ndph.ox.ac.uk/data-access</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_access_criteria>See URL</ipd_access_criteria>
    <ipd_url>https://www.ndph.ox.ac.uk/data-access</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan: Induction Therapy Data Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01120028/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 19, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01120028/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Maintenance Therapy Data Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01120028/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>3C was conducted in 18 transplant centres in the UK. Recruitment took place between October 2010 and July 2013.</recruitment_details>
      <pre_assignment_details>852 participants were randomized for a comparison of Alemtuzumab (426) and Basiliximab (426) based induction therapies. After 6-months, 394 of those participants were re-randomized to either Sirolimus (197) or Tacrolimus (197) based maintenance therapies.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Period 1: Alemtuzumab/Tacrolimus</title>
          <description>Induction therapy allocation: Alemtuzumab (Campath-1H) and Tacrolimus
Alemtuzumab: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
Tacrolimus: Target trough level 5-7 ng/mL for 6-months after alemtuzumab.</description>
        </group>
        <group group_id="P2">
          <title>Period 1: Basiliximab/Tacrolimus</title>
          <description>Induction therapy allocation: Basiliximab and Tacrolimus
Basiliximab: 20 mg intravenously, two doses 96 hours apart
Tacrolimus: Target trough level 5-12 ng/mL for 6-months after basiliximab</description>
        </group>
        <group group_id="P3">
          <title>Period 2: Sirolimus</title>
          <description>Sirolimus maintenance therapy: target trough level of 6-12 ng/mL for the first 6-months, then reducing to 5-10 ng/mL.</description>
        </group>
        <group group_id="P4">
          <title>Period 2: Tacrolimus</title>
          <description>Tacrolimus maintenance therapy: target trough level of 5-7 ng/mL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Alemtuzumab or Basiliximab</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="426"/>
                <participants group_id="P2" count="426"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="412"/>
                <participants group_id="P2" count="403"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not transplanted</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: Tacrolimus or Sirolimus</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="197"/>
                <participants group_id="P4" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="197"/>
                <participants group_id="P4" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
      <group_list>
        <group group_id="B1">
          <title>Period 1: Alemtuzumab/Tacrolimus</title>
          <description>Induction therapy allocation: Alemtuzumab (Campath-1H) and Tacrolimus
Alemtuzumab: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart.
Tacrolimus: Target trough level 5-7 ng/mL for 6-months after alemtuzumab.</description>
        </group>
        <group group_id="B2">
          <title>Period 1: Basiliximab/Tacrolimus</title>
          <description>Induction therapy allocation: Basiliximab and Tacrolimus
Basiliximab: 20 mg intravenously, two doses 96 hours apart.
Tacrolimus: Target trough level 5-12 ng/mL for 6-months after basiliximab.</description>
        </group>
        <group group_id="B3">
          <title>Period 2: Sirolimus</title>
          <description>Sirolimus maintenance therapy: target trough level of 6-12 ng/mL for the first 6-months, then reducing to 5-10 ng/mL.</description>
        </group>
        <group group_id="B4">
          <title>Period 2: Tacrolimus</title>
          <description>Tacrolimus maintenance therapy: target trough level of 5-7 ng/mL.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="426"/>
            <count group_id="B2" value="426"/>
            <count group_id="B3" value="197"/>
            <count group_id="B4" value="197"/>
            <count group_id="B5" value="1246"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age, Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="347"/>
                    <measurement group_id="B2" value="350"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="697"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age, Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="197"/>
                    <count group_id="B4" value="197"/>
                    <count group_id="B5" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="163"/>
                    <measurement group_id="B4" value="162"/>
                    <measurement group_id="B5" value="325"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age, Continuous, Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="13.3"/>
                    <measurement group_id="B2" value="51.8" spread="13.3"/>
                    <measurement group_id="B5" value="51.9" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age, Continuous, Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="197"/>
                    <count group_id="B4" value="197"/>
                    <count group_id="B5" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="51.7" spread="13.0"/>
                    <measurement group_id="B4" value="52.0" spread="12.9"/>
                    <measurement group_id="B5" value="51.8" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sex, Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex, Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="197"/>
                    <count group_id="B4" value="197"/>
                    <count group_id="B5" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="132"/>
                    <measurement group_id="B5" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnic origin, Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="370"/>
                    <measurement group_id="B2" value="372"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="742"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnic origin, Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="197"/>
                    <count group_id="B4" value="197"/>
                    <count group_id="B5" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="173"/>
                    <measurement group_id="B5" value="347"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All 852 participants were recruited in the UK.</description>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="197"/>
                    <count group_id="B4" value="197"/>
                    <count group_id="B5" value="1246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Period 1: United Kingdom</title>
                  <measurement_list>
                    <measurement group_id="B1" value="426"/>
                    <measurement group_id="B2" value="426"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="852"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Period 2: United Kingdom</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="197"/>
                    <measurement group_id="B4" value="197"/>
                    <measurement group_id="B5" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Renal Disease</title>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Primary Renal Disease: Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Diabetic kidney disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Glomerulonephritis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="181"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Polycystic kidney disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chronic pyelonephritis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hypertension</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Renovascular disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary renal disease, Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="197"/>
                    <count group_id="B4" value="197"/>
                    <count group_id="B5" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Diabetic kidney disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Glomerulonephritis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Polycystic kidney disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chronic pyelonephritis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hypertension</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Renovascular disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other Previous Disease</title>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diabetes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B5" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancer</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous renal replacement</title>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Haemodialysis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="457"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Peritoneal dialysis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="210"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Transplant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HLA mismatch level</title>
          <description>HLA = human leucocyte antigen.
Level 1: 0-0-0; Level 2: 0 HLA-DR and 0/1 HLA-B mismatches; Level 3: (0 HLA-DR and 2 HLA-B) or (1 HLA-DR and 0/1 HLA-B); Level 4: (1 HLA-DR and 2 HLA-B) or (2 HLA-DR).
Level 1 being most favourable, Level 4 being least favourable.</description>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>HLA mismatch level, Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Level 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Level 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="188"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Level 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="389"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Level 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLA mismatch level, Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="197"/>
                    <count group_id="B4" value="197"/>
                    <count group_id="B5" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Level 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Level 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Level 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Level 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous transplant</title>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Previous transplant, Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="782"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous transplant, Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="197"/>
                    <count group_id="B4" value="197"/>
                    <count group_id="B5" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="181"/>
                    <measurement group_id="B4" value="181"/>
                    <measurement group_id="B5" value="362"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Highly sensitised</title>
          <description>Highly sensitised is defined as calculated reaction frequency &gt;85% where the calculated reaction frequency is the proportion of the general UK population that the participant is predicted to be sensitised against.</description>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Highly sensitized, Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="410"/>
                    <measurement group_id="B2" value="411"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Highly sensitized, Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="197"/>
                    <count group_id="B4" value="197"/>
                    <count group_id="B5" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="193"/>
                    <measurement group_id="B4" value="190"/>
                    <measurement group_id="B5" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Virology serology</title>
          <description>CMV=cytomegalovirus; EBV=Epstein-Barr virus.</description>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CMV-positive donor to negative recipient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B5" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EBV-positive donor to negative recipient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of donor</title>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Type of donor, Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Donation after brain death</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="293"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Donation after circulatory death</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="316"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Donation from living (related or unrelated) person</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type of donor, Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="197"/>
                    <count group_id="B4" value="197"/>
                    <count group_id="B5" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Donation after brain death</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Donation after circulatory death</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Donation from living (related or unrelated) person</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor sex</title>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="422"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="372"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cold ischaemia time (h)</title>
          <description>For deceased donor transplants only.</description>
          <population>Period 1: Baseline data (852 participants) at randomization to induction therapy (Alemtuzumab or Basiliximab).
Period 2: 6-months post-transplantation, baseline data (394 of the original participants) at re-randomization to maintanence therapy (Sirolimus or Tacrolimus).</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="426"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="5.7"/>
                    <measurement group_id="B2" value="12.9" spread="6.0"/>
                    <measurement group_id="B5" value="13.4" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy</title>
        <description>Occurence of biopsy-proven acute rejection events at 6-months after transplantation during Period 1 (randomization to induction therapy (Campath-1H and Tacrolimus, or Basiliximab and Tacrolimus))</description>
        <time_frame>6 months post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 1: Alemtuzumab/Tacrolimus</title>
            <description>Induction therapy allocation: Alemtuzumab (Campath-1H) and Tacrolimus
Alemtuzumab: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
Tacrolimus: Target trough level 5-7 ng/mL for 6-months after alemtuzumab.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Basiliximab/Tacrolimus</title>
            <description>Induction therapy allocation: Basiliximab and Tacrolimus
Basiliximab: 20 mg intravenously, two doses 96 hours apart
Tacrolimus: Target trough level 5-12 ng/mL for 6-months after basiliximab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy</title>
          <description>Occurence of biopsy-proven acute rejection events at 6-months after transplantation during Period 1 (randomization to induction therapy (Campath-1H and Tacrolimus, or Basiliximab and Tacrolimus))</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Graft Function (at 18-months After Randomization to Maintenance Therapy)</title>
        <description>Estimated glomerular filtration rate (estimated using MDRD formula) at 18-months after maintenance therapy randomization to either Sirolimus or Tacrolimus.</description>
        <time_frame>2 years post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 2: Sirolimus</title>
            <description>Sirolimus maintenance therapy: target trough level of 6-12 ng/mL for the first 6-months, then reducing to 5-10 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: Tacrolimus</title>
            <description>Tacrolimus maintenance therapy: target trough level of 5-7 ng/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Function (at 18-months After Randomization to Maintenance Therapy)</title>
          <description>Estimated glomerular filtration rate (estimated using MDRD formula) at 18-months after maintenance therapy randomization to either Sirolimus or Tacrolimus.</description>
          <units>mL/min/1.73m²</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" spread="0.9"/>
                    <measurement group_id="O2" value="54.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Failure (at 6-months After Randomization to Induction Therapy)</title>
        <description>Return to dialysis or re-transplantation by 6-months after randomization to induction therapy.</description>
        <time_frame>6 months post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 1: Alemtuzumab/Tacrolimus</title>
            <description>Induction therapy allocation: Alemtuzumab (Campath-1H) and Tacrolimus
Alemtuzumab: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
Tacrolimus: Target trough level 5-7 ng/mL for 6-months after alemtuzumab.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Basiliximab/Tacrolimus</title>
            <description>Induction therapy allocation: Basiliximab and Tacrolimus
Basiliximab: 20 mg intravenously, two doses 96 hours apart
Tacrolimus: Target trough level 5-12 ng/mL for 6-months after basiliximab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Failure (at 6-months After Randomization to Induction Therapy)</title>
          <description>Return to dialysis or re-transplantation by 6-months after randomization to induction therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Failure (at 18-Months After Randomization to Maintenance Therapy)</title>
        <description>Return to dialysis or re-transplantation by 18-months after randomization to maintenance therapy.</description>
        <time_frame>2 years post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 2: Sirolimus</title>
            <description>Sirolimus maintenance therapy: target trough level of 6-12 ng/mL for the first 6-months, then reducing to 5-10 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: Tacrolimus</title>
            <description>Tacrolimus maintenance therapy: target trough level of 5-7 ng/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Failure (at 18-Months After Randomization to Maintenance Therapy)</title>
          <description>Return to dialysis or re-transplantation by 18-months after randomization to maintenance therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Log Rank</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>6.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Infection (at 6-months After Randomization to Induction Therapy)</title>
        <description>Occurrence of any serious infection (opportunistic or requiring admission to hospital) reported within Period 1 (randomization to induction therapy of either Alemtuzumab (Campath-1H) and Tacrolimus, or Basiliximab and Tacrolimus).</description>
        <time_frame>6-months post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 1: Campath 1H/Tacrolimus</title>
            <description>Induction therapy allocation: Campath-1H and Tacrolimus
Alemtuzumab: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
Tacrolimus: Target trough level 5-7 ng/mL for 6-months after alemtuzumab.</description>
          </group>
          <group group_id="O2">
            <title>Period 1: Basiliximab/Tacrolimus</title>
            <description>Induction therapy allocation: Basiliximab and Tacrolimus
Basiliximab: 20 mg intravenously, two doses 96 hours apart
Tacrolimus: Target trough level 5-12 ng/mL for 6-months after basiliximab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Infection (at 6-months After Randomization to Induction Therapy)</title>
          <description>Occurrence of any serious infection (opportunistic or requiring admission to hospital) reported within Period 1 (randomization to induction therapy of either Alemtuzumab (Campath-1H) and Tacrolimus, or Basiliximab and Tacrolimus).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Regression, Cox</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Infection (at 18-months After Randomization to Maintenance Therapy)</title>
        <description>Occurrence of any serious infection (opportunistic or requiring admission to hospital) reported during Period 2 (maintenance therapy randomization to either Sirolimus or Tacrolimus).</description>
        <time_frame>2 years post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 2: Sirolimus</title>
            <description>Sirolimus maintenance therapy: target trough level of 6-12 ng/mL for the first 6-months, then reducing to 5-10 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: Tacrolimus</title>
            <description>Tacrolimus maintenance therapy: target trough level of 5-7 ng/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Infection (at 18-months After Randomization to Maintenance Therapy)</title>
          <description>Occurrence of any serious infection (opportunistic or requiring admission to hospital) reported during Period 2 (maintenance therapy randomization to either Sirolimus or Tacrolimus).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Log Rank</method>
            <param_type>Rate ratio</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cancer (at 18-months After Randomization to Maintenance Therapy)</title>
        <description>Occurrence of any cancer reported during Period 2 (maintenance therapy randomization to either Sirolimus or Tacrolimus).</description>
        <time_frame>2 years post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 2: Sirolimus</title>
            <description>Sirolimus maintenance therapy: target trough level of 6-12 ng/mL for the first 6-months, then reducing to 5-10 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: Tacrolimus</title>
            <description>Tacrolimus maintenance therapy: target trough level of 5-7 ng/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cancer (at 18-months After Randomization to Maintenance Therapy)</title>
          <description>Occurrence of any cancer reported during Period 2 (maintenance therapy randomization to either Sirolimus or Tacrolimus).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Log Rank</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Vascular Event (at 18-months After Randomization to Maintenance Therapy)</title>
        <description>Composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death or arterial revascularization</description>
        <time_frame>2 years post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 2: Sirolimus</title>
            <description>Sirolimus maintenance therapy: target trough level of 6-12 ng/mL for the first 6-months, then reducing to 5-10 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Period 2: Tacrolimus</title>
            <description>Tacrolimus maintenance therapy: target trough level of 5-7 ng/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Vascular Event (at 18-months After Randomization to Maintenance Therapy)</title>
          <description>Composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death or arterial revascularization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Log Rank</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Period 1: SAEs collected during the 6-months post-transplantation Period 2: SAEs collected between 6-months and 24-months post-transplantation</time_frame>
      <desc>Information about the occurrence of serious adverse events was recorded at scheduled visits
Other (not including Serious) Adverse Events were not recorded or assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Period 1: Alemtuzumab/Tacrolimus</title>
          <description>Induction therapy allocation: Alemtuzumab (Campath-1H) and Tacrolimus
Alemtuzumab: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
Tacrolimus: Target trough level 5-7 ng/mL for 6-months after alemtuzumab.</description>
        </group>
        <group group_id="E2">
          <title>Period 1: Basiliximab/Tacrolimus</title>
          <description>Induction therapy allocation: Basiliximab and Tacrolimus
Basiliximab: 20 mg intravenously, two doses 96 hours apart
Tacrolimus: Target trough level 5-12 ng/mL for 6-months after basiliximab</description>
        </group>
        <group group_id="E3">
          <title>Period 2: Sirolimus</title>
          <description>Maintenance therapy allocation: Sirolimus
Target trough level of 6-12 ng/mL for the first 6-months then reducing to 5-10 ng/nL</description>
        </group>
        <group group_id="E4">
          <title>Period 2: Tacrolimus</title>
          <description>Maintenancy therapy allocation: Tacrolimus
Target trough level of 5-7 ng/mL</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="341" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="354" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="134" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familial and genetic disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy, puerperium and perinatal conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social circumstances</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="426"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Peter Friend</name_or_title>
      <organization>University of Oxford</organization>
      <phone>01865223872</phone>
      <email>ccc@ctsu.ox.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

